Gene · 481
NIH grants1,651
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 1,651
Download this page as JSON| Grant | Title | ATP1B1 papers | Newest fiscal year |
|---|---|---|---|
| R01AI137067 | Translational Regulation of T Regulatory Cells | 1 | 2025 |
| R01AI160706 | Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy | 1 | 2025 |
| R01CA136367 | Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated Herpesvirus | 1 | 2025 |
| R01CA163336 | Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data | 1 | 2025 |
| R01CA200900 | Systemic RNA Delivery to Tumors | 1 | 2025 |
| R01DA037927 | Discovery of Addiction-Related Genes with Advanced Mouse Resources | 1 | 2025 |
| R01DC013294 | Modeling Inner Ear Differentiation with Pluripotent Stem Cells | 1 | 2025 |
| R01DE026644 | Targeting Signaling Vulnerabilities for Oral Cancer Prevention | 1 | 2025 |
| R01DE031044 | Salivary gland ionocyte organization and function during homeostasis, repair, and disease | 1 | 2025 |
| R01DK048370 | Small GTP Binding Proteins in Gastrointestinal Mucosa | 1 | 2025 |
| R01DK054231 | Molecular of ROMK Channel Function | 1 | 2025 |
| R01DK061931 | Mechanisms and pathophysiologic impact of claudin-2 modulation | 1 | 2025 |
| R01DK067536 | Role of IGF-1 and insulin receptors beta-cell survival | 1 | 2025 |
| R01DK068271 | Therapeutic targeting of protein interactions to reverse MLCK1-mediated intestinal barrier loss and ameliorate disease. | 1 | 2025 |
| R01DK071865 | Molecular Mechanisms of Active Copper Transport | 1 | 2025 |
| R01DK072381 | Kidney Injury Molecule-1 in Epithelial Repair | 1 | 2025 |
| R01DK073368 | Mechanisms of Compartmentalized cAMP Signaling | 1 | 2025 |
| R01DK110375 | Coordinated SLC12A3/SLC12A6/SL26A4 electroneutral transport pathways maintain K+ homeostasis and acid-base balance | 1 | 2025 |
| R01DK112984 | Podocyte-Proximal Tubule Interactions in Diabetic Kidney Disease | 1 | 2025 |
| R01DK121101 | The role of cyclin G1 and CDK5 in chronic kidney disease. | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/481/grants?page=7